Research
Hormonal
Tirzepatide has similar gastrointestinal adverse reactions and contraindications as traditional GLP-1 receptor agonists.
Clinicians should be aware of the potential for similar side effects when prescribing tirzepatide.
StrongSupportsmedium confidence
Tirzepatide has similar gastrointestinal adverse reactions and contraindications as traditional GLP-1 receptor agonists.
Why this rating
The claim is based on comparative safety information from the abstract.
Source
Tirzepatide: Clinical review of the “twincretin” injectable
Zach Krauss et al. · American Journal of Health-System Pharmacy · 2023
DOI 10.1093/ajhp/zxad080
reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →